期刊文献+

Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors

Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors
原文传递
导出
摘要 We designed a series of 2-methylpyrimidine derivatives as new BCR-ABL inhibitors using scaffold-hopping strategy.These synthetic compounds exhibited significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I mutant.Compound 7u showed very potent kinase inhibitory activities against Bcr-Abl WT,Bcr-Abl E255K,Bcr-Abl Q252H,Bcr-Abl G250E and Bcr-Abl T315I,with IC50 values of 0.13 nM,0.17 nM,0.24 nM,0.19 nM and 0.65μM,respectively.This compound also displayed anti-proliferation activity against K562 cell line with an IC50 value of 1.1 nM,thus representing a new lead for further optimization. We designed a series of 2-methylpyrimidine derivatives as new BCR-ABL inhibitors using scaffold-hopping strategy.These synthetic compounds exhibited significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I mutant.Compound 7u showed very potent kinase inhibitory activities against Bcr-Abl WT,Bcr-Abl E255K,Bcr-Abl Q252H,Bcr-Abl G250E and Bcr-Abl T315I,with IC50 values of 0.13 nM,0.17 nM,0.24 nM,0.19 nM and 0.65μM,respectively.This compound also displayed anti-proliferation activity against K562 cell line with an IC50 value of 1.1 nM,thus representing a new lead for further optimization.
出处 《Science China Chemistry》 SCIE EI CAS 2014年第6期823-832,共10页 中国科学(化学英文版)
基金 supported by the National Natural Science Foundation of China(21172220) the National Basic Research Program of China(2009CB940900)
关键词 chronic myeloid leukemia(CML) anticancer agents BCR-ABL imatinib resistance 嘧啶衍生物 抑制剂 生物学评价 合成化合物 平移 K562细胞 IC50 抑制活性
  • 相关文献

参考文献31

  • 1Heisterkamp N, Stam K, Groffen J, de Klein, A, Grosveld G. Structural organization of the bcr gene and its role in the Ph8 translocation. Nature, 1985, 315: 758-761.
  • 2Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. New Engl J Med, 2003, 349: 1451-1464.
  • 3Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 1996, 88: 2375-2384.
  • 4Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol, 1995, 15: 5531-5541.
  • 5Goga A, McLaughlin J, Afar DEH, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell, 1995, 82: 981-988.
  • 6Carlesso LN, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med, 1996, 183: 811-820.
  • 7Shuai K, Halpner J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene, 1996, 13: 247-254.
  • 8Sattler M, Salgia R, Okuda K, Uemura N, Durstin M, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD. The protooncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ ABL and p210BCR/ABL to the phosphatidylinositol-38 kinase pathway. Oncogene, 1996, 12: 839-846.
  • 9Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selec-tive inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med, 1996, 2: 561-566.
  • 10Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355: 2408-2417.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部